Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple pill replace painful shots for new moms at risk of clots?

NCT ID NCT07716332

Disease control Sponsor: Ron Beloosesky MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study compares two blood-thinning medicines given after delivery to prevent dangerous blood clots: apixaban (a pill taken twice a day) and enoxaparin (a daily shot). The trial enrolls women at high risk for clots after vaginal or cesarean birth. The main goal is to see which treatment is more convenient and easier for mothers to stick with, while also tracking safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
apixaban (oral tablet) compared to enoxaparin (subcutaneous injection)
What this could lead to
If oral apixaban works as well as the injection, it could offer new mothers a simpler, less painful way to prevent dangerous blood clots after childbirth.
What could go wrong
This is a small study focused on convenience, not on proving apixaban prevents clots better. It may not detect rare safety issues like bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * After Vaginal or C/S delivery. * Need prophylactic treatment in a preventive dose. * Presence of one or more high risk factors: Active infection, IBD, Heart disease, Type 1 diabetes with nephropathy, IV drug user, Surgical operation in Postpartum period, Emergency cesarean section. OR presence of 2 low risk factors: Age \> 35, post-partum hemorrhage \> 1000 ml, Cesarean section, Hysterectomy, BMI \> 30, Multiparity- Third birth or more, Active Smoking, Obstetric complications in current pregnancy (including preeclampsia, preterm birth before 37 weeks, active infection including chorioamnionitis, prolonged labor over 24 hours), Twin birth, Immobility, Large varicose veins, Stillbirth Exclusion Criteria: * Breast feeding. * Predispose to hypercoagulability * Familial history of VTE. * Antiphospholipid syndrome (APS). * Prior VTE. * Anticoagulant treatment before or during pregnancy. * BMI \> 40 * History of severe renal or hepatic disease. * Use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. * Known diagnosis of bleeding dyscrasia (eg, von Willebrand disease). * Spinal/epidural hematoma or spinal puncture. * Active pathological bleeding or high risk of bleeding. * Hemoglobin \> 9 mg/dl before the delivery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DVT prophylaxis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

puerperal disorder venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DVT prophylaxis Postpartum

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.